Formulated to alleviate severe autoimmune inflammation to support joint mobility and target chronic tissue degradation.
Mechanism of Action
Binds specifically to TNF-alpha, neutralizing its interaction with cell surface receptors to halt the inflammatory cascade.
Route of Administration
Subcutaneous
Onset Time
2–4 weeks
Duration
10–14 days
Contraindications
Severe active infection, Moderate to severe congestive heart failure
Severe Adverse Events
Severe systemic sepsis — requires immediate medical attention, Malignancy development — requires immediate medical attention, Demyelinating disease activation — requires immediate medical attention
Information related to Humira is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
